Legal Representation
Attorney
Christopher D. Olszyk, Jr.
USPTO Deadlines
Next Deadline
63 days remaining
NOA E-Mailed - SOU Required
Due Date
March 25, 2026
Extension Available
Until September 25, 2026
Application History
13 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 25, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 25, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Sep 25, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Sep 25, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 25, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 28, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 28, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 22, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 7, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 5, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 3, 2025 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jan 3, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 13, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in the treatment of seizures, bipolar disorders, depression, amyotrophic lateral sclerosis, migraines, Parkinson's disease, neurofibromatosis, chronic obstructive pulmonary disease, and ophthalmology-related disorders including dry eye and glaucoma; Pharmaceutical preparations for the prevention and treatment of central nervous system disorders, neurological diseases and disorders, neurodegenerative disorders, depression and ophthalmology-related disorders including dry eye and glaucoma; Pharmaceutical preparations for the treatment of seizures in epilepsy, mood changes in bipolar disorders and depression, reduction in symptoms associated with amyotrophic lateral sclerosis, migraines, Parkinson's disease, and ophthalmology-related disorders including dry eye and glaucoma, chronic obstructive pulmonary disease, and lesion reduction in neurofibromatosis, each administered via drug delivery agents in the form of liquids, extended-release oral solids, inhalation, liquid nasal sprays, powder nasal sprays, and topical formulations that facilitate the delivery of pharmaceutical preparations.
Additional Information
Design Mark
The mark consists of a stylized inverted triangle design inside a square.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005